Pharmaceutical press releases - Bristol Myers Squibb

20/11/24

Bristol Myers Squibb welcomes Health Technology Assessment Reform Implementation Advisory Group announcement

19/11/24

Bristol Myers Squibb Australia Presents the Patient & Parliament Summit: Partnering for Patients

21/01/24

New treatment for melanoma set to be reimbursed

03/01/24

BMS announces new General Manager for Australia and New Zealand

29/11/23

Bristol Myers Squibb Australia launches Innovate RAP

08/11/23

Bristol Myers Squibb Australia has been named on the 2023 Australia's Best Workplaces™ for Women List

16/10/23

Bristol Myers Squibb Australia Presents the Patient and Parliament Summit: Medicines for All - Unlocking Universal Patient Access

08/10/23

New reimbursed treatment for Aussie adults living with common inflammatory skin disease – psoriasis

17/08/23

BMS Australia listed as part of Great Place to Work’s Best Workplaces

29/05/23

Bringing Patient Centricity to Life

15/05/23

BMS Australia receives accreditation from Great Places to Work

01/05/23

New treatment option now reimbursed for Australians living with an incurable inflammatory bowel disease

28/04/23

BMS Australia supports Uluru Statement from the Heart

13/02/23

Bristol Myers Squibb Australia supports efforts to defeat melanoma and skin cancer

01/11/22

Bristol Myers Squibb Australia has been named on the 2022 Best Workplaces for Women List

23/10/22

New leadership for BMS Australia and New Zealand

03/10/22

First treatment in 10 years PBS listed for Aussies living with aggressive stomach & oesophageal cancers

03/10/21

National Medicines Policy – BMS response

21/06/21

New treatment for Aussies living with asbestos-related cancer

01/03/21

New treatment for most common form of MS now available on PBS

30/05/20

New combination therapy now reimbursed for Australians living with incurable blood cancer

30/03/20

Australians living with an incurable blood cancer set to receive new reimbursed treatment option

30/08/19

Four weekly dosing of immuno-oncology treatment for cancer patients available on the PBS from 1st September 2019

27/02/19

Combination immuno-oncology treatment for Kidney Cancer patients available on the PBS from 1st March 2019

28/11/18

First combination immuno-oncology treatment available on pharmaceutical benefits scheme from 1st December

14/10/18

New leader for Bristol Myers Squibb in Australia and New Zealand

24/09/18

First Combination Immunotherapy for Advanced Kidney Cancer Approved for use in Australia

25/07/18

OPDIVO now PBS listed for treatment of advanced head and neck cancer (consumer version)

19/06/18

OPDIVO now TGA approved for adjuvant treatment of advanced melanoma (consumer version)

23/07/17

NSCLC PBS listing (consumer version)

23/07/17

RCC PBS listing (consumer)

22/11/16

OPDIVO (nivolumab) approved for advanced kidney cancer.

01/11/16

New BMS patient resource: a guide to immuno-oncology.

29/04/16

OPDIVO (nivolumab) listed on the PBS for the treatment of advanced melanoma.

27/03/16

New BMS guides published about access to medicines in Australia.

16/03/16

OPDIVO (nivolumab) approved for advanced non squamous non-small cell lung cancer.

28/02/16

Daklinza (daclatasvir) listed on the PBS for chronic hepatitis C.

29/01/16

Immuno-oncology agent Opdivo (nivolumab) approved for advanced melanoma & lung cancer.

07/06/15

BMS Australia – Best employer 3rd year running.

Read Bristol Myers Squibb’s stories about life & science